Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

Summary: The discovery that mutations in the EGFR gene are detected in up to 50% of lung adenocarcinoma patients, along with the development of highly efficacious epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of this frequently occurring...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaojing Du, Biwei Yang, Quanlin An, Yehuda G. Assaraf, Xin Cao, Jinglin Xia
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2021-05-01
coleção:	The Innovation
Assuntos:	Cancer targeted therapy EGFR inhibitors drug resistance mutations chemoresistance mechanisms
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S266667582100028X
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!